HC Wainwright Reaffirms “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reissued by research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports.

Other research analysts also recently issued reports about the stock. Barclays decreased their price target on shares of Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 5th. Royal Bank Of Canada raised their target price on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a report on Thursday, January 8th. Guggenheim lowered their target price on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Wells Fargo & Company reduced their price target on Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Finally, Piper Sandler raised their price objective on Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th. Nine research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $33.84.

Sarepta Therapeutics Stock Down 3.9%

SRPT stock opened at $21.31 on Tuesday. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -7.08, a P/E/G ratio of 0.55 and a beta of 0.48. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95. The business’s 50-day moving average is $21.41 and its two-hundred day moving average is $19.87. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $120.05.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). The business had revenue of $399.36 million for the quarter, compared to analysts’ expectations of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. Sarepta Therapeutics’s revenue for the quarter was down 14.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.62 EPS. As a group, analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Insider Transactions at Sarepta Therapeutics

In related news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. The trade was a 6.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SRPT. Vanguard Group Inc. boosted its position in shares of Sarepta Therapeutics by 18.1% during the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after acquiring an additional 1,657,267 shares during the last quarter. First Trust Advisors LP lifted its stake in Sarepta Therapeutics by 209.1% in the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock worth $37,380,000 after purchasing an additional 1,312,220 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Sarepta Therapeutics by 183.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock valued at $33,627,000 after purchasing an additional 1,129,610 shares during the last quarter. Erste Asset Management GmbH grew its position in shares of Sarepta Therapeutics by 65.7% during the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after purchasing an additional 1,064,530 shares in the last quarter. Finally, Federated Hermes Inc. increased its holdings in shares of Sarepta Therapeutics by 347.8% in the second quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company’s stock worth $22,370,000 after purchasing an additional 1,016,069 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Key Stories Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Three-year EMBARK topline results show sustained motor gains and slower disease progression for ELEVIDYS in Duchenne muscular dystrophy, supporting the therapy’s long-term value and lifting investor sentiment. SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
• Positive Sentiment: An analyst upgrade and bullish note prompted a sharp intraday jump (reports of ~13.9% move), reflecting short-term momentum from favorable coverage. Sarepta Therapeutics (NASDAQ:SRPT) Trading Up 13.9% After Analyst Upgrade
• Neutral Sentiment: Coverage roundup pieces discuss the healthcare peer group and provide broader analyst context but don’t add new company-specific catalysts. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Several write-ups reassess valuation after recent short-term momentum — useful for longer‑term investors but not an immediate catalyst. Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Short-Term Share Price Momentum
• Negative Sentiment: Barclays initiated coverage with an “equal weight” rating and a $20.00 price target, which is below the current level and signals limited upside from here. (No link provided)
• Negative Sentiment: HC Wainwright reaffirmed a sell rating, keeping downside sentiment from some institutional analysts. Benzinga Coverage
• Negative Sentiment: Citi reiterated a bearish view — citing safety uncertainty and label risk around ELEVIDYS — and maintained a sell/high-risk stance, which contributes to negative near-term sentiment. Sarepta Therapeutics: Safety Uncertainty and Label Risk Overshadow Elevidys Data

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.